Xlife Sciences AG (SIX: XLS) announced that shareholders approved all proposals presented at the company’s Annual General Meeting, where 3,134,367 voting shares, representing 54.3% of the total share capital, were represented. The approval underscores shareholder confidence in the company’s strategic direction and portfolio development.
Chairman David L. Deck highlighted that the company strengthened its portfolio over the past year, pointing to the Nasdaq listing of portfolio company Veraxa Biotech (NASDAQ: VRXA) and the planned Landsteiner Scientific platform as key milestones supporting the next phase of growth. The Veraxa Biotech listing marks a significant achievement, providing access to deeper capital markets and increased visibility for the company’s innovations.
The company emphasized the strategic importance of the planned Landsteiner Scientific platform, which is intended to accelerate the identification and development of novel therapeutic approaches while improving global market access for Xlife Sciences’ portfolio companies. Management said the platform will integrate academic research with commercial development and serve as a cornerstone of the company’s future innovation pipeline, while also outlining upcoming capital markets activities.
Xlife Sciences focuses as an incubator and accelerator on the value development and commercialization of promising research projects from universities and other research institutions in the life sciences sector, aiming to provide solutions for high unmet medical needs. The company selects projects in technological platforms, biotechnology/therapies, medical technology, and artificial intelligence/digital health.
For more information, visit www.xlifesciences.ch. To view the full press release, see https://ibn.fm/nfUvM.
